Literature DB >> 32502978

Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.

En Cheng1, Peiyin Hung2,3, Shi-Yi Wang1,4.   

Abstract

BACKGROUND: Transplantation, surgical resection, radiofrequency ablation, and percutaneous ethanol injection are generally considered potentially curative treatments for patients with hepatocellular carcinoma (HCC). With the increasing incidence of HCC, it is critical to investigate geographic variations in curative treatments and their associations with survival among patients.
METHODS: A total of 6,782 patients with HCC during 2004 to 2011 were identified in the SEER-Medicare linked database and placed in quartiles based on the proportions undergoing potentially curative treatments per hospital referral region (HRR). Hierarchical Cox proportional hazards models were used to examine the association between regional potentially curative treatment patterns and survival across quartiles.
RESULTS: An average of 16.9% of patients with HCC underwent potentially curative treatments during 2004 to 2011, varying substantially from 0% to 34.5% across HRRs. Compared with patients residing in the lowest-quartile regions, those in the highest-quartile regions were more likely to be of other races (vs white or black), be infected with hepatitis B virus, and have more comorbidities. The 5-year survival was 4.7% in the lowest-quartile regions and 11.4% in the highest-quartile regions (P<.001). After controlling for confounders, patients in the highest-quartile regions had a lower risk of mortality (adjusted hazard ratio, 0.78; 95% CI, 0.72-0.85).
CONCLUSIONS: Patients with HCC who resided in HRRs with higher proportions of potentially curative treatments had better survival. Given its proven survival benefits, prompt clinical and policy actions are needed to reduce variations in treatment utilization.

Entities:  

Mesh:

Year:  2020        PMID: 32502978     DOI: 10.6004/jnccn.2020.7529

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  3 in total

1.  Caveat Emptor: 2-Year Follow-Up Evaluating Post-Resection Liver Decompensation in Patients with Underlying Cirrhosis and Incident Hepatocellular Carcinoma.

Authors:  Dhavan Shah; Bona Ko; David J Bentrem
Journal:  Ann Surg Oncol       Date:  2021-10-15       Impact factor: 5.344

Review 2.  Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review.

Authors:  Abdalla Aly; Sarah Ronnebaum; Dipen Patel; Yunes Doleh; Fernando Benavente
Journal:  Hepat Oncol       Date:  2020-07-21

3.  Epidemiology and Outcomes of Hospitalizations Due to Hepatocellular Carcinoma.

Authors:  Sanjana Mullangi; Praneeth R Keesari; Anas Zaher; Yashwitha Sai Pulakurthi; Frank Adusei Poku; Arathi Rajeev; Prasanna Lakshmi Vidiyala; Asha Latha Guntupalli; Maheshkumar Desai; Jessica Ohemeng-Dapaah; Yaw Asare; Achint A Patel; Manidhar Lekkala
Journal:  Cureus       Date:  2021-12-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.